SPPI, ABT, ORFG, – PennyToBuck.com Watch List For Monday May 2nd!
pennytobuck Newsletter
__ ABT, Abbott Laboratories Male hypogonadism (or low testosterone) is a condition in which the body does not produce enough testosterone, the hormone that plays an important role in a mans growth and development.
Signs and symptoms associated with male hypogonadism include erectile dysfunction and decreased sexual desire, fatigue and loss of energy, depressed mood, osteoporosis and a diminishment in the physical characteristics of a man, such as decreased body hair.
Nearly 14 million men in the United States may have low testosterone levels. The Endocrine Society developed guidelines for the diagnosis and treatment of hypogonadism, which note the normal range for testosterone as 300-1,000 ng/dL (nanograms/deciliter).
ABT is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics.
ABT reported that the U.S. Food and Drug Administration has approved AndroGel (testosterone gel) 1.62%, a clear, odorless, gel formulation shown to restore testosterone levels in hypogonadal men with half the volume of gel at the starting dose compared to AndroGel 1%.
At the starting dose, the new AndroGel 1.62% contains 40.5 mg of testosterone in two pump presses, whereas AndroGel 1% contains 50 mg of testosterone in four pump presses. Dosage and administration for AndroGel 1.62% differs from AndroGel 1% and the two are not interchangeable.
Both AndroGel 1.62% and AndroGel 1% are prescription medications used to treat adult males with low or no testosterone, also known as hypogonadism.
With the approval of AndroGel 1.62% (which is expected to be available to patients in the second quarter of 2011), ABT now offers another innovation in testosterone delivery for men with hypogonadism to treat their condition.
More about ABT at www.abbott.com ******************
SPPI, Spectrum Pharmaceuticals, Inc.
Colon cancer can almost always be caught by colonoscopy in its earliest and most curable stages. Almost all men and women age 50 and older should have a colon cancer screening. Patients at risk may need earlier screening.
Colon cancer screening can often find polyps before they become cancerous. Removing these polyps may prevent colon cancer.
Almost all colon cancer starts in glands in the lining of the colon and rectum. When doctors talk about colorectal cancer, this is usually what they are talking about.
Many cases of colon cancer have no symptoms. The following symptoms, however, may indicate colon cancer:
– Abdominal pain and tenderness in the lower abdomen – Blood in the stool – Diarrhea, constipation, or other change in bowel habits – Narrow stools – Weight loss with no known reason According to the American Cancer Society, colorectal cancer is the third most commonly diagnosed cancer and the third leading cause of cancer death in both men and women in the US, with approximately 141,210 new cases and 49,380 deaths expected in 2011.
SPPI is a biotechnology company with fully integrated commercial and drug development operations with a primary focus in oncology. The Companys strategy is comprised of acquiring, developing and commercializing a broad and diverse pipeline of late-stage clinical and commercial products. SPPI markets two oncology drugs, FUSILEV and ZEVALIN and has two drugs, apaziquone and belinostat, in late stage development along with a diversified pipeline of novel drug candidates.
** FDA Approves FUSILEV for Use in Patients with Colorectal Cancer **
SPPI reported that it has received approval from the U.S. Food and Drug Administration (FDA) for the use of FUSILEV (levoleucovorin) in combination with 5-fluorouracil in the palliative treatment of patients with advanced metastatic colorectal cancer. This new, expanded indication supplements the original 2008 FDA approval of FUSILEV.
FUSILEV (levoleucovorin), under various trade names, has been available in Europe and Japan primarily by Wyeth, Sanofi-Aventis, and Takeda Pharmaceuticals. It is estimated that ex-U.S. sales of Levoleucovorin are in excess of $180 million a year.
**Furthermore, for the First Quarter 2011, SPPI recently reported product estimated revenues (unaudited) in excess of $40 million, a nearly six-fold increase as compared to approximately $7 million in the first quarter 2010.
More about SPPI at www.sppirx.com ******************
ORFG, Orofino Gold Corp., ORFG.PK It is known to all that the primary use of gold is associated to jewelry. About 78% of the gold consumed each year goes in the manufacture of different jewelry products.
Although primarily used as a store of value, gold has many modern industrial uses including dentistry and electronics. Gold has traditionally found use because of its good resistance to oxidative corrosion and excellent quality as a conductor of electricity.
If the doom and gloom predictions of the global economys future do come to fruition, many analysts predict the value of gold could continue on its long-term upward trend, topping $2000 US per ounce in the next couple of years.
Colombia, the fourth largest nation in South America, is a country with a lot of natural treasures. Colombias economy is mostly depended on agriculture and mining.
Colombia is rich in natural resources, and its main exports include petroleum, coal, coffee and other agricultural produce, and gold.
Colombias gold mines are now much talked about in the world.
Colombia is recognized as one of the most prospective, yet under-explored countries in the world, and provides an attractive blend of gold, copper and silver deposit discovery potential within a pro-mining business atmosphere.
ORFG has several Gold development properties in Colombia, a current hot spot of gold production in the world markets.
ORFG`s Board of Directors unanimously appointed Dr. Hans Bocker as the new Chairman of the Board. His expertise encompasses fundamental organizational and operational logistics including production and operations management, purchasing and procurement, safety, loss control, quality management, international management, cross-cultural management, transportation and traffic logistics, and leadership training for executives. He is is also an internationally recognized gold expert.
** Laboratory test results and historical data indicates high grades for ORFG`s mining areas + Recently, ORFG released the results of an updated technical report on its mining concessions in Sur de Bolivar, Colombia.
This 2010 report confirms and reinforces the promising findings of previous claim holders. This initial report was produced on behalf of ORFG by Thomas H. Carpenter, P.Geo of Discovery Consultants, ORFG`s Geological Consultants hired to assist with the production of a comprehensive 43-101 compliant report.
Mr. Carpenter`s findings reiterate the potential of ORFG`s concessions and why Guavita S.A., Metallica Resources, AngloGold, and others have valued them over the years. Mr. Carpenter`s confirmation of earlier analysis is assisting ORFG as it progresses toward ultimate development of these sought-after claims.
To read the full report, click here http://www.orofinogoldcorp.com/pdf/sur-de-bolivar-report.pdf + Furthermore, additional laboratory test results from random chip samples within ORFG`s Culo Alzado mining area, on the north margin of Senderos de Oro, in Colombia indicate high grades.
A complete listing of Acme Analytical Laboratories reports is available here. http://www.orofinogoldcorp.com/pdf/culo-alzado-report.pdf + Additional laboratory test results from random chip samples within ORFG`s La Azul mining area in Colombia, indicate very high grades.
A complete listing of Acme Analytical Laboratories reports is available here. http://www.orofinogoldcorp.com/pdf/la-azul-report.pdf ORFGs corporate objective is to continue to build shareholder value through the exploration and development of The Senderos de Oro Gold Camp and additional accretive acquisitions, capitalizing on the extensive experience and relationships that management has developed over the past 25 years More about ORFG at www.orofinogoldcorp.com.
*****************************
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY! Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. PennyToBuck.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer (http://pennytobuck.com/disclaimer) is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold PennyToBuck.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period. Crown Equity Holdings Inc. (CRWE.OB) has previously received 500,000 shares of (144) restricted common stock and 500,000 shares of free trading shares from a third party (QU CUI You) for six months of advertisement services (which has expired) for Orofino Gold Corp. (PINK SHEETS:ORFG).
— The following information is a reminder of your current mailing list subscription:
You are subscribed to the following list:
pennytobuck.com
Related posts: